Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German ...

News of the offer arrived days after Bloomberg reported that the private equity group Triton Partners, which has built an ...

The private equity firm Triton Partners is reportedly considering acquiring Evotec, Bloomberg reported, citing people familiar with the matter. In an SEC filing, Evotec reported that Triton had ...

Triton Partners, is considering a takeover bid Evotec , Eyk Henning of Bloomberg reported earlier, citing people familiar with the matter. Triton is among several investment firms ...

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...

Triton Partners is considering a takeover bid for Germany’s Evotec SE, according to people familiar with the matter, after the private equity firm emerged as one of the drug developer’s ...

Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall around ...